CORRECTION: On Thursday March 21, 2024 ARS Pharmaceuticals Reported Q4 EPS $(0.07) Beats $(0.14) Estimate
Company Profile
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.